PARTNERSHIP FOR ACHIEVING TOTAL HEALTH PelEX

Section: HIPAA		Subject: PATH DATA USE, RETENTION AND DISCLOSURE POLICY			
Controls Addressed:	Regulations Security (A)	Controls 45 CFR 164.308(a)(1)			
Applies to: ☑ PATH ☑ Business Partner			Effective from: 6-15-2012	Revised on: 7-25-2023	Page 1 of 2
Approved: 5-22-2012, 9-6-2023 (RECC) Revised 2-9-2023, 7-25-2023, 9/6/2023 Revised 7-24-2023: rebranded to PelEX					

I. PURPOSE

The Data Use, Retention and Disclosure policy aims to ensure that PelEX and Participants appropriately use and disclose health information consistent with sound policy and in accordance with applicable law. Establishing protocols related to how protected health information (PHI) can be used and disclosed is essential to build trust among members.

II. SCOPE

This policy applies to PelEX, Participants, and data stored within PelEX.

III. POLICY STATEMENT

This policy describes the Partnership for Achieving Total Health (PATH's) responsibility, as the primary project manager and fiduciary agent of PelEX, as it relates to data use and disclosure of information available through PelEX. Establishing requirements around data use and disclosure in permissible situations is critical to sharing data electronically. PATH is responsible for guarding against Unauthorized Use and improper disclosure of PHI available through PelEX.

1. PelEX shall not disclose any information to an unauthorized entity. PATH is responsible for the appropriate use and disclosure of information through PelEX.

2. PelEX shall require Participants to limit the use and disclosure (including re-disclosure) of information obtained through the system for purposes related to treatment, payment and health operations (TPO) and other Services. PelEX does allow Participants to disclose electronic health information obtained through the system, as appropriate, to authorized business associates that have signed a Business Associates Agreement (BAA) with the Participant that is at least as protective as PelEX's BAA.

3. PelEX shall include in its BAA and as applicable Terms and Conditions the rules for use and disclosure of information obtained through the system to ensure that data made available through the system is not inappropriately used or disclosed.

4. In the event a patient opts out of PelEX, PelEX will prohibit further sharing of such data, except in emergencies, within a reasonable amount of time but no more than 10 business days of receiving the opt-out notice. Data that was shared prior to the election of the patient's opt-out notice cannot be recalled.

5. PelEX will inform Participants to whom they redisclosed PHI of amendments made to PHI in accordance with 45 C.F.R. Section 164.526

6. PATH shall verify the authenticity of subpoenas, court orders, or discovery requests for the disclosure of PHI maintained on PelEX. PATH's legal counsel will be consulted upon receipt of these documents, and if appropriate, shall confer with counsel for any affected participants. PelEX shall respond to these requests in a timeframe consistent with existing law.

7. PelEX shall not release data for marketing or commercial purposes and shall require Participants to adhere to the same requirements. The use of consumer information available through PelEX for purposes other than TPO and approved Services is prohibited by PelEX and all Participants.